Evidence map›Paper›PMID 31336362›Full record

ArticleEndocrine connections2019

Evaluation of CYP17A1 and CYP1B1 polymorphisms in male breast cancer risk.

Piera Rizzolo, Valentina Silvestri, Virginia Valentini, Veronica Zelli, Agostino Bucalo, Ines Zanna, Simonetta Bianchi, Maria Grazia Tibiletti, Antonio Russo, Liliana Varesco and 13 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Endocrine connections, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 12 institutions in 1 country.

Piera RizzoloDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Valentina SilvestriDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Virginia ValentiniDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Veronica ZelliDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Agostino BucaloDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Ines ZannaCancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy.
Simonetta BianchiDivision of Pathological Anatomy, Department of Sciences of Health, University of Florence, Florence, Italy.
Maria Grazia TibilettiDepartment of Pathology, ASST Settelaghi and Centro di Ricerca per lo Studio dei Tumori Eredo-Familiari, Università dell'Insubria, Varese, Italy.
Antonio RussoSection of Medical Oncology, Department of Surgical and Oncological and Oral Sciences, University of Palermo, Palermo, Italy.
Liliana VarescoIRCCS Ospedale Policlinico San Martino, Genoa, Italy.
Gianluca TedaldiBiosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Bernardo BonanniDivision of Cancer Prevention and Genetics IEO, European Institute of Oncology IRCCS, Milan, Italy.
Jacopo AzzolliniUnit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan, Italy.
Siranoush ManoukianUnit of Medical Genetics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori (INT), Milan, Italy.
Anna CoppaDepartment of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Giuseppe GianniniDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Laura CortesiDepartment of Oncology and Haematology, University of Modena and Reggio Emilia, Modena, Italy.
Alessandra VielUnit of Functional Onco-Genomics and Genetics, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.
Marco MontagnaImmunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
Paolo PeterlongoGenome Diagnostics Program, IFOM - The FIRC Institute of Molecular Oncology, Milan, Italy.
Paolo RadiceUnit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Research, Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy.
Domenico PalliCancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy.
Laura OttiniDepartment of Molecular Medicine, Sapienza University of Rome, Rome, Italy.
Sapienza University of Rome · ITFondazione IRCCS Istituto Nazionale dei Tumori · ITCentro di Riferimento Oncologico · ITEuropean Institute of Oncology · ITFIRC Institute of Molecular Oncology · ITIstituto Oncologico Veneto · ITIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori · ITOspedale Policlinico San Martino · ITUniversity of Florence · ITUniversity of Insubria · ITUniversity of Modena and Reggio Emilia · ITUniversity of Palermo · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer in men is a rare and still poorly characterized disease. Inherited mutations in BRCA1, BRCA2 and PALB2 genes, as well as common polymorphisms, play a role in male breast cancer genetic predisposition. Male breast cancer is considered a hormone-dependent tumor specifically related to hyperestrogenism. Polymorphisms in genes involved in estrogen biosynthesis and metabolism pathways, such as CYP17A1 and CYP1B1, have been associated with breast cancer risk. Here, we aimed to investigate the role of CYP17A1 and CYP1B1 polymorphisms in male breast cancer risk. A series of 597 male breast cancer cases and 1022 male controls, recruited within the Italian Multicenter Study on male breast cancer, was genotyped for CYP17A1 rs743572, CYP1B1 rs1056836 and rs1800440 polymorphisms by allelic discrimination real-time PCR with TaqMan probes. Associations with male breast cancer risk were estimated using logistic regression. No statistically significant associations between male breast cancer risk and the three analyzed polymorphisms emerged. Similar results were obtained also when BRCA1/2 mutational status was considered. No significant differences in the distribution of the genotypes according to estrogen receptor status emerged. In conclusion, our study, based on a large series of male breast cancer cases, is likely to exclude a relevant role of CYP17A1 and CYP1B1 polymorphisms in male breast cancer predisposition. Overall, these results add new data to the increasing evidence that polymorphisms in these genes may not be associated with breast cancer risk.

Indexed as

CYP17A1CYP1B1male breast cancermale breast cancer riskpolymorphisms

Identifiers

PMID31336362
PMCPMC6733362
OpenAlexW2963920902

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.